Home Biotechnology North America Genetic Testing Market Analysis, Trends, Forecast Up to 2030

North America Genetic Testing Market

Select Regional / Country Report

North America Genetic Testing Market Size, Share & Trends Analysis Report By Diagnosis Type (Biopsy, Imaging), By Technology (Sequencing, PCR, Microarray), By End User (Diagnostic Centres, Hospital, Clinics) and By Country(US, Canada) Forecasts, 2024-2032

Report Code: SRBI3235DR
Study Period 2020-2032 CAGR 12.4%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The North America region is expected to reach 12915 million USD by 2030 with a CAGR of 12.4% in North America Genetic Testing Market.

A genetic test is a type of medical testing that is carried out with the purpose of determining whether or not there have been any alterations to the chromosomal structure or the DNA sequence. Either the gene included within the DNA sequence can be directly recognised through the sequencing process or indirectly identified through a variety of methods of genetic testing. The use of genetic testing in the diagnosis of rare diseases and the practise of customised medicine is expanding at a rapid rate.

The pandemic caused by COVID-19 has had a substantial influence on the expansion of the market for genetic testing during the course of the crisis. According to the study report that was published in Genetics in Medicine 2020, all clinical genetic testing was halted, and consultations and counselling based on telemedicine were implemented worldwide. According to the findings of this research, a total of 156 clinical genetics and cancer patients as well as 112 pregnant patients were assessed over the course of one month at the Columbia University Irving Medical Center (CUIMC). In order to stop the spread of the SARS-CoV2 virus, the vast majority of genetic testing businesses have begun using virtualization, and many of them also provide home testing kits and collect samples from patients in their own homes. However, according to the research article that was published in the Journal of Medical Genetics 2020, there was a hindrance reported in accessing genetic testing blood draws. As a consequence of this hindrance, the genetic testing was tremendously impacted, wherein a reduction in genetic testing from 97.7% to 74.1% was observed during the period in which virtual care was provided. As a result, it is anticipated that COVID-19 will have both a direct and an indirect influence on the market for genetic testing during the current crisis time.

In addition, the growing number of technology improvements that have occurred over the course of the previous few years have made various prospects for market development available. The rapid expansion of the market is being aided by a number of factors, including an increase in the incidence of chronic illnesses and the creation of specialised testing kits for specialised treatment areas. According to the World Population Prospects 2020 Highlights published by the United Nations, there will be more than 1.5 billion people over the age of 65 years by the year 2050, which is an increase from 727 million in the year 2020. Because of the rising number of elderly people and their increased risk of developing chronic illnesses, there has been an uptick in the need for preventative diagnostics, in particular genetic testing.

The increased attention that governments of various countries are placing on regulating genetic testing and raising knowledge about them has effectively resulted in a speedier acceptance of these tests all around the world. Increased spending on research and development, along with large firms' already established footholds in the market, has made it difficult for new companies to break into the industry. Maintaining a competitive advantage in the market requires a number of critical characteristics to be satisfied, including innovation in product design, improvement in quality, and strong distribution relationships. For instance, in August 2020, Ricoh Company Ltd. and DNA Chip Research Inc. produced RICOH Standard DNA Series EGFR mutation Type001, which is a reference DNA plate to be utilised in the blood-based genetic testing in the diagnosis of lung cancer. This plate is intended to be used by many companies.

Market Dynamics


Testing that is both predictive and presymptomatic is applied in the process of identifying gene variants that are linked to conditions that manifest after birth, most typically in later stages of one's life. Even if the person undergoing testing does not currently exhibit any symptoms of the genetic condition, it may still be beneficial for them to have the test if they have a family member who suffers from the condition. Testing that is predictive can help in the detection of mutations that might raise the likelihood of an individual acquiring a condition, such as in the case of certain malignancies. As a result, the growing rates of cancer and more knowledge about the illnesses are anticipated to lead to an increase in the number of individuals undergoing these tests, which in turn is anticipated to drive the market in North America.

In addition, there has been an increase in the proportion of the population that is getting older, which has led to an increase in the number of people being diagnosed with chronic diseases, as well as an increase in the number of people being diagnosed with cancer. These are all significant factors that are contributing to the expansion of the North America genetic testing market in North America. As a result of the rising occurrence of genetic diseases, new prospects for genetic testing and the uses of genetic information have become apparent. It is projected that the change of the genetic testing industry from one that is driven by services to one that is driven by products would encourage diagnostic firms to expand their operations.


The expansion of the genetic testing industry in North America is hampered by a number of problems, including the enormous expenses connected with genetic testing and the absence of conventional standards concerning the legitimacy of genetic findings.

Regional Analysis

The North American regional market has a considerable market share throughout the period covered by the projection and is anticipated to expand at a high compound annual growth rate (CAGR). Additionally, it is anticipated that the United States would produce additional money on the country level.

There were an estimated 16.9 million cancer survivors living in the United States as of January 2019, according to data provided by the National Cancer Institute. In addition, the number of people who have survived cancer is expected to rise up to 22.2 million by the year 2030. One of the key growth boosters for the North American market has been the increasing use of sophisticated cancer therapy choices. This trend has been compounded by the rising prevalence of cancer.

In addition, the Dana Farber Cancer Institute launched the Center for BRCA and Related Genes in August of 2020, with the intention of preventing BRCA-related malignancies through this introduction. Therefore, the increase in product approvals from the Food and Drug Administration (FDA) of the United States and the high concentration of significant players for the launch of breakthrough North America genetic testing market products are jointly driving the expansion of the market.

Furthermore, the initiatives taken by the federal government to raise awareness of diseases, favourable reimbursement policies, an increase in the demand for better patient care, technological advancements, a well-established medical infrastructure, and an increase in the number of people in their later years are definitively driving the growth of the market in the North America region.

Report Scope

Report Metric Details
By Diagnosis Type
  1. Biopsy
    1. Blood Sample
    2. Cheek Swab Sample
  2. Imaging
By Technology
  1. Sequencing
  2. PCR
  3. Microarray
By End User
  1. Diagnostic Centres
  2. Hospital
  3. Clinics
Company Profiles Myriad Genetics, Inc Abbott Laboratories Thermo Fisher Scientific Illumina, Inc. Bio-Rad Laboratories, Inc. Danaher Corporation PerkinElmer, Inc. Agilent Technologies, Inc Quest Diagnostics Luminex Corporation
Geographies Covered
North America US Canada
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Recent Developments

The clinical Whole Genome Sequencing Services division of PerkinElmer was introduced in May of 2021. It is predicted that the new launch would stimulate growth in the market for cancer North America genetic testing market.

AncestryHealth was powered by the Next Generation Sequencing Engine, which was introduced by Quest Diagnostics in August of 2020. It is anticipated that the creation of the new product would lead to an increase in the revenue of the firm.

Top Key Players

North America Genetic Testing Market Share of Key Players

Myriad Genetics, Inc Abbott Laboratories Thermo Fisher Scientific Illumina, Inc. Bio-Rad Laboratories, Inc. Danaher Corporation PerkinElmer, Inc. Agilent Technologies, Inc Quest Diagnostics Luminex Corporation

Frequently Asked Questions (FAQs)

How big is the North America market?
The North America region is expected to reach 12915 million USD by 2030 with a CAGR of 12.4% in North America Genetic Testing Market.
Key verticals adopting the North America market include: Myriad Genetics, Abbott Laboratories, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, Danaher Corporation, PerkinElmer, Agilent Technologies, Quest Diagnostics, Luminex Corporation, Inc
By Diagnosis Type, By Technology and By End User are the main segmentations of North America market.

We are featured on :